Novartis Forecasts Profit Gains Despite Copycat Competition
(MENAFN- Swissinfo)
Swiss Pharmaceutical heavyweight Novartis said profit will rise this year as new medicines help offset competition from copycats of its best-selling drug.
This content was published on
January 31, 2025 - 10:05
2 minutes
Bloomberg
+ Get the most important news from Switzerland in your inbox
Core operating profit will likely grow by a high single- to a low double-digit percentage, outpacing sales, the Swiss drugmaker said Friday.
Novartis is facing patent expiries for three key drugs, with top-selling heart medicine Entresto expected to face generic competitors in the US mid-year. The drugmaker says its newer therapies will continue to drive growth.
The patent expiries are a test of CEO Vas Narasimhan's years-long overhaul of the company, with its focus narrowed to specific types of diseases. Last year Narasimhan issued what many investors saw as a cautious forecast at the beginning of the year, then repeatedly raised it in successive quarters.
Sales will probably increase at a mid- to high-single digit pace this year, Novartis said. The drugmaker reported a 7% increase in fourth-quarter net income to $2.8 billion.
Besides Entresto, two of Novartis's top 20 drugs, Tasigna for leukemia and Promacta for blood clotting, will face generics in the US. But they have successors: the company anticipates more than 15 regulatory submissions or approvals for key drugs this year.
Novartis shares have risen about 1% in the past 12 months, less than those of cross-town rival Roche. Roche on Thursday said profit excluding some items would probably grow in the high single-digit range at constant currencies this year.
©2025 Bloomberg L.P.
MENAFN01022025000210011054ID1109155568
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.